Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CXCR4 | P61073 | 4/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342819 | 0.95 | MEN1 (0.44) | MEN1KMT2ACXCR4TSHRALOX15 | |
| SCHEMBL9213719 | 0.88 | CXCR4 (0.49) | CXCR4TSHRALDH1A1 | |
| SCHEMBL4362890 | 0.82 | ALDH1A1 (0.45) | MEN1KMT2ATSHRALOX15ALDH1A1 | |
| SCHEMBL21427272 | 0.82 | CXCR4 (0.55) | CXCR4ALDH1A1 | |
| SCHEMBL18911326 | 0.81 | MEN1 (0.46) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL9217160 | 0.80 | LMNA (0.48) | MEN1KMT2ATSHRALDH1A1 | |
| SCHEMBL12629018 | 0.80 | KMT2A (0.44) | MEN1KMT2ACXCR4ALDH1A1MAPT | |
| SCHEMBL31365998 | 0.79 | SIGMAR1 (0.43) | — | |
| SCHEMBL4359522 | 0.78 | BACE1 (0.39) | MEN1KMT2ATSHRALOX15ALDH1A1 | |
| SCHEMBL9205301 | 0.78 | EGLN1 (0.40) | MEN1KMT2AALOX15ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268810-B2 | Lipophilic chelates and their use in imaging | GUERBET (FR) | 2012-09-18 | — | — | US | disclosed |
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | GUERBET (FR) | 2009-08-27 | — | — | US | disclosed |
| EP-1885721-B1 | METAL CHELATES OF POLYAMINOCARBOXYLIC MACROCYCLIC DERIVATIVES AND USE THEREOF IN DIAGNOSTIC IMAGING | GUERBET SA (FR) | 2009-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214441-A1 | Lipophilic Chelates and Their Use in Imaging | SLC40A1, TSPO, SLC47A2 | MEN1 941/4885KMT2A 1704/4885CXCR4 337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.